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Strap:  Legal highs 
Title: Novel Psychoactive Substances (NPS): no longer legal, not always highs 
 
Standfirst:  Use of legal highs amongst students is on the rise.  As counsellors it is 
difficult to stay abreast of what young people are using and the effects that 
substances can have.  John Turner and Kirstie Soar guide us through some of the 
terminology and the effects commonly reported and highlight appropriate responses 
from counsellors. 
 “I was at a club – this guy gave me something and I took it – I’ve been feeling really 
woozy ever since.  Now I’m really worried about what it was and what it might be 
doing to me.”  
“Smoking ‘spice’ or whatever it was, has had such an awful effect on me. Even now 
a year later I can’t shake the paranoia and anxiety, and just feel I’ve lost part of my 
sanity because of the way the experience made me feel and the things I think I saw. 
I wish I could go back, and it makes me cry to think of other people my age and 
younger, especially kids, going through this” (experience of a young man who tried a 
synthetic cannabis-like novel psychoactive, taken from an online chat forum). 
It’s not uncommon for clients to have experimented with substances of one kind or 
another and to want to talk about this in sessions.  Staying abreast of the myriad of 
substances available and their possible impact is a challenge for us all, and has 
become more so in recent years with the rise of novel psychoactive substances. 
 
Since the early 2000s the rebranding of rarely used psychoactive substances as 
legal alternatives to banned drugs, and the creation of novel/new psychoactive 
substances (NPS), has dramatically gathered pace.1 In Europe alone the European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is currently attempting to 
keep records on the manufacture, distribution, use and effects of 450 NPS, with an 
additional 101 new substances being reported as available in one or more of the 28 
member states in the year 2014 to 2015 alone.1 
Previously referred to as ‘legal highs’, NPS are now more tightly controlled in the UK 
following the introduction of the Psychoactive Substances Bill in May 2016. Under 
this change to UK law it is now illegal to manufacture, sell and use all psychoactive 
substances (these being substances “capable of producing a psychoactive effect”,), 
except for named exemptions which include caffeine, nicotine, alcohol, various 
medicines and food-related products.3 However, with concerns about how this new 
legislation will be enforced, mixed regulation across the EU and other countries 
worldwide, and the simple fact that illegal drug use is widespread, it is likely that NPS 
use will remain relatively commonplace. An illustrative example of this relates to use 
of mephedrone, once a ‘legal high’ but banned in the UK in early 2010. A study 
monitoring use in the same London club venues both before and after the ban, 
showed use and self-reported preferences for mephedrone as being sustained and 
even increased after the drug had become illegal4. 
Current knowledge of NPS is limited, and understanding the exact effects of 
individual drugs, for acute use, chronic consumption and when used in combinations 
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with other substances, is challenged by the ever changing contexts of availability, 
quality of product and evolution of new drugs. What is clear is that NPS use amongst 
younger populations in the UK has grown considerably. For example, recent 
evidence found that almost one third (31 per cent) of participants in a study of 446 
users of an online young adult UK student general forum (The Study Room), 
reported using an NPS.5 Taken together we have a worrying situation where large 
numbers of predominantly younger individuals are experimenting with these poorly 
understood compounds. Given this landscape practitioners especially are faced with 
having to work with and support individuals who may be experiencing problems 
related to or exacerbated by NPS use. We suggest therefore, that the best way 
forward in this context is to utilise a combination of the limited knowledge we do have 
about individual NPS, often gleaned from case studies and small scale research, 
with the broader understanding that we already have of different drug class effects. 
Many of these NPS were designed to mimic and replace illegal drugs, and so this 
stance is a reasonable foundation for working intelligently with clients; perhaps 
especially so in non-clinical settings such as schools, colleges and universities, 
where currently little direct guidance for counsellors exists, but where drug 
experimentation is commonplace.  As with so many issues, awareness informs 
compassion and understanding and helps in coping with the anxieties we may feel 
when working with issues beyond our own direct experience. 
Types and classes of NPS 
Looking at the NPS which have entered the legal and illegal drug markets in recent 
years, the EMCDDA describe most as belonging to one of 5 main drug groups based 
on the molecular chemical family to which they belong: stimulatory phenethylamines 
and piperazines; hallucinogenic tryptamines; cathinone analogues; and synthetic 
cannabinoids.2 Not all identified NPS fit these established categories and so some 
are more broadly classified as ‘others’; these may include plant based NPS, and 
drugs which mimic the dissociative anaesthetic ketamine. It is by the EMCDDA 
categorisation that we refer to NPS groupings here.  However, it is important to note 
that there are inconsistencies in classification of NPS in the research literature and 
clinical guidance, and across EU countries.  Indeed the usefulness to front line 
clinicians and practitioners in classifying these varied substances based on their 
molecular structure is not especially clear, and users themselves tend to categorise 
NPS based on their psychotropic effects. Classification is made even more complex 
by NPS vendors who use suggestive marketing in their packaging or brand names; 
alluding more to the overall effect of the NPS as a stimulant, psychedelic, sedative 
etc. rather than categorising them by their drug molecular similarities.6 Despite the 
UK ban, and closure of shops selling direct to consumers, international online sellers 
are likely to remain ubiquitous for the time being, and so these ‘branding issues’ will 
persist. 
 
Table 1 below lists the five EMCDDA drug groups and provides a few illustrative 
examples of NPS for each. The table excludes details of ‘street’ or product names, 
as these are changeable and unpredictable, and so of considerably less utility to 
practitioners in non-specialist settings, compared to the reported experiences and 
behaviours of the user.7 The table also lists possible problems that may be evident 
following sustained use, high doses or which might present in more susceptible 
individuals, and those with other psychological problems, current or historical. 
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Table 1: Examples of NPS categorised by their perceived pharmacological effects/actions (and in 
line with EMCDDA drug group classifications) 
Category Examples of NPS Effects Potential psychological 
problems 
Phenethylamines NBOM-e subtypes (e.g. 25n, 25b); 
2C-B ; 2C-I; 5-APB; 6-APB 
Stimulant and/or 
hallucinogenic 
hallucinations, agitation 
Piperazines mCPP; BZP; TFMPP; MBZP Stimulant psychosis, panic attacks, 
hallucinations, insomnia, 
anxiety, agitation 
Tryptamines DMT; AMT; 4-OH-MET; 5-Meo-
DALT; 4-OH-DiPT 
Hallucinogenic and 
stimulant properties 
hallucinations 
Cathinones Mephedrone; Methylone; 
Methcathione; MDPV ; MDPPP 
Stimulant and 
empathogenic effects 
(MDMA/ecstasy-like)  
agitation, psychotic 
symptoms, hallucinations, 
risk of dependency 
Synthetic 
cannabinoids 
(cannabis-like) 
Spice; JWH-018; AB-FUBINACA Depressant, sedative, 
hallucinogenic, but 
some stimulant 
properties 
agitation, aggression, 
paranoid thinking, 
anxiety, hallucinations, 
psychotic symptoms, 
addiction, confusion  
Others 5-APDB 
6-APDB 
Stimulant (derivative of 
MDA) 
psychosis, panic attacks, 
hallucinations, insomnia, 
anxiety, agitation 
3-MeO-PCP Ketamine-like 
(derivative of PCP) 
derealisation, distorted 
reality, hallucinations, 
confusion, agitation, 
depressive thoughts 
MXE  Ketamine-like effects, 
stimulant, depressant, 
anti-depressant, 
hallucinogenic, and 
analgesic effects. 
Salvia divinorum Hallucinogenic hallucinations, alterations 
in reality, panic attacks, 
paranoid thoughts 
 
In terms of prevalence, the growth of alternatives to cannabis (synthetic 
cannabinoids) has been reported to have shown the most dramatic increases in 
types and demand in recent data sets.2 However, these same data also show that 
stimulant types are being produced at a comparable level, if the very wide range of 
different new stimulant substances are summed across the separate classes. 
Because these two groups of NPS (synthetic cannabinoids and the mixed stimulant 
types) are clearly the most widely used the rest of this article will concentrate a little 
more on what is known about their effects, and about the possible problems that may 
arise from use. 
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Synthetic cannabinoids: Synthetic cannabinoids are generally sold and consumed as 
a cannabis-like leaf product, often consisting of the psychoactive chemical sprayed 
onto herbs (e.g. thyme, mint), which can be smoked, vaporised or ingested in the 
same fashion as cannabis. These NPS are designed as alternatives to cannabis and 
its main psychoactive ingredient Δ-9-tetrahydrocannabinol (THC), and appear to be 
largely consumed to induce comparable states of relaxation, euphoria and altered 
consciousness. 8 The synthetic cannabinoids vary considerably in their chemical 
structure but all appear to act as agonists at endocannabinoid receptors in the 
central nervous system, producing overall effects similar to THC.9 However, many 
appear to be associated with more psychosis-like and agitation effects, and to 
produce greater sympathomimetic effects (e.g. raised heart rate, palpitations, 
sweating, muscle tension etc.) compared to organic cannabis. For example, 
Papaneti and colleagues’ systematic review of the widely popular synthetic 
cannabinoid varieties known as ’Spice’, found increased prevalence of hallucinations 
and psychotic symptoms following both acute and chronic use.10 Winstock and 
Barratt investigated adverse experiences relating to synthetic cannabinoid products 
in 950 people who had used synthetic cannabinoids in the last year, with 2.4 per cent 
having reportedly sought emergency medical treatment, noting prominent increased 
anxiety and agitation.11 Those who sought medical treatment were usually 
significantly younger (average age 20) than those who did not (average age 23), and 
this suggests potential age differences in anxiety-related responses to synthetic 
cannabinoids in users.  
These negative effects may in part be due to the fact that the synthetic cannabinoids, 
as simple THC analogues, lack the more complex pharmacological profile 
attributable to other psychoactives naturally found in cannabis, most importantly 
cannabidiol (CBD). CBD has been reported to have both anxiolytic and antipsychotic 
effects. Fortunately, for most individuals adversely affected, the effects of synthetic 
cannabinoids appear to be short lasting and to resolve upon drug cessation and so 
may need little more than short-time monitoring and supportive care.12 Nonetheless, 
the effects of long term exposure and follow-up profiles of affected users are under-
researched, although one study has shown evidence of prolonged psychosis in a 
small subset of users.12 In addition, although work looking in detail at the issue of 
dependence on synthetic cannabinoids is limited, case study work,13 and a survey 
study 8 have suggested some users may have significant symptoms and find 
discontinuation problematic. Given that many of these drugs exert similar or more 
powerful central effects compared to THC, it is certainly not surprising that signs of 
dependency may be observable in some regular users.9 
 
Stimulant type NPS: The majority of stimulant type NPS are sold in powdered form 
(sometimes under the guise of plant food or bathing products) or as tablets, with 
users tending to snort, ingest or smoke the substance. The reasons for taking NPS 
with stimulant effects mirror those generally given for use of other legally available 
and illicit stimulants. Amongst other effects, these substances are commonly 
reported to induce euphoria, create a sense of energy and general stimulation, to 
enhance cognitive states and to facilitate social interaction and sexual experiences. 
14 As with many other psychostimulants, in addition to recreational use it is possible 
that many of these substances, possibly at lower doses, could be seen by some 
users as aiding study/work, reducing fatigue and need for sleep, and as enhancing 
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concentration and performance. Additionally, it is also worth noting that as with most 
other stimulants (especially amphetamine-type stimulants; ATS), NPS stimulants are 
also likely to have strong anorectic effects, though comparative effects of different 
types on appetite suppression has not yet been systematically documented. 
With the phenethylamine based substances, the core chemical structure is designed 
to mimic that of more purely stimulant drugs such as amphetamine, 
methamphetamine and cocaine; and as such this group of compounds are often 
classed as ATS.15 However, similar to most potent stimulants, many of the 
phenethylamine NPS appear to have some hallucinogenic properties. With regards 
to negative effects, high levels of intoxication have been associated with anxiety, 
insomnia, aggression, paranoia and psychosis, effectively mirroring effects 
frequently seen with high doses of amphetamine. Many users also appear to show a 
hangover from use (or ‘come down’) often lasting several days after use, with 
experiences such as mood disturbance, irritability and restlessness, and somatic 
symptoms such as pain and fatigue.15 
 
The piperazines also produce similar effects to amphetamine. As such, in addition to 
the stimulant effects of heightened arousal and cognitive states, they are associated 
with often powerful sympathomimetic effects, which at high doses are capable of 
creating severe agitation and adverse cardiovascular symptoms (referred to as the 
sympathomimetic toxidrome).16 There is some evidence that piperazine compounds 
have at times been mis-sold as ecstasy/MDMA, and so users’ reports of what they 
believe they have taken may show a mismatch with their descriptions of adverse 
effects which instead relate more to exposure to a piperazine. Piperazines appear 
more likely to cause hallucinatory experiences than many other NPS stimulants, and 
more so than ecstasy, so user reports of this effect may help practitioners to better 
establish what might have been taken. 
 
Current understanding of the effects of cathinones (originally derived from the khat 
plant) is largely based on studies looking at mephedrone, as the most widely used of 
all drugs in this class. This substance, and other cathinones, share similar properties 
to both MDMA/ecstasy and methamphetamine/amphetamine, although they are 
generally seen as less potent. However, overlap in effects with these drugs has been 
argued to make mephedrone, and most likely the other cathinones, both particularly 
appealing to young people and club goers, and to have a high potential for 
dependence. 15 The recent guidance from the Novel Psychoactive Treatment UK 
Network (NEPTUNE) also highlights reports of co-use of mephedrone with 
methamphetamine in club settings, and in particular this combination being used as 
part of the ‘Chem Sex’ scene in London, largely amongst men who have sex with 
men.15 This may be especially worrying as the combination of these two 
psychostimulants may enhance the negative effects of both drugs when used 
individually. More generally negative effects associated with cathinone use again 
mimic those seen with other stimulants, though severe effects are most likely 
associated with longer periods of use and/or use of high doses and combinations 
with other substances. 16 
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Table 2: Some considerations for practitioners working with clients who use or may have used NPS 
Questions/considerations Comment 
1. Is the individual aware of changes to UK 
law? There are no ‘legal highs’ anymore 
The ubiquity of products online may give the 
false impressions that some/all substances they 
can buy are legal in the UK – none of them are, 
and so they may be breaking the law 
 
2. If they’ve been taking NPS, what effects 
have they experienced? 
The user may think they know what they have 
taken, but they cannot be certain, so the effects 
can help to at least ascertain class 
 
3. Need to establish whether any distress 
reported has a history beyond or prior to 
NPS use 
As with other substance use assessments it is 
important to try to establish the origins of the 
client’s distress and advise about the role their 
NPS and other drug use might be having 
 
4. Screen for dependence Does the use of any NPS type/class show 
evidence of meeting dependence criteria? 
 
5. Need to discuss extent of use, combined 
use and raise awareness of pertinent issues 
Use of multiple types of NPS and other 
substances can be managed in the same fashion 
as other complex drug use patterns, taking into 
consideration the classes being used. Multiple 
use of different stimulants and combinations of 
powerful stimulants with alcohol are of 
particular concern for general health and 
wellbeing, as well as linked to areas such as 
aggression, affective problems and sexual risk 
taking 
 
6. General health and wellbeing As for other substance use – ask about weight 
change, poor performance in study/work, poor 
skin condition, chest pains/breathing problems, 
stomach upsets, etc. With obvious intoxication 
or significant poor health symptoms immediate 
hospital/emergency services support should be 
sought 
 
7. Financial/legal complications With changes to legislation, continued NPS use 
may see a rise in people charged with related 
offences; possible pricing adjustments; debts 
linked to dependence 
 
8. General lack of knowledge about NPS As with other substances (but perhaps 
exacerbated by the sheer numbers/types) users 
of illicit substances cannot be sure of content or 
strength of substances purchased. We also know 
very little about the consequences of use, 
especially long-term use 
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Conclusion 
Research documenting the physical and psychological effects experienced by 
regular and current users of NPS (who have not experienced severe effects to the 
point of hospitalisation) is limited, with most data relating to prevalence of use 
through demographic research. Studies to date do however raise significant 
concerns about the harm related to use of many of these substances. Synthetic 
cannabinoids may trigger or amplify negative psychological symptoms seen with 
regular cannabis use, through their often more potent effects, producing in some 
users severe anxiety, troubling hallucinations and possibly even psychosis. The wide 
range of stimulant-like NPS also appear problematic for some individuals, producing 
significant negative mood changes, psychosis, dependence and increasing rates of 
sexual risk-taking and regretted sex. Although not covered in detail here, other NPS 
classes may also be problematic, for example with hallucinatory/psychedelic types 
capable of producing profound hallucinations which, as with classic hallucinogens, 
might lead to flashback type experiences and possibly more persistent problems.  
 
The extent of these problems in users is currently difficult to determine, and the 
sheer numbers of substances available, discerning which have been taken, at what 
doses and in which combinations complicates understanding immeasurably. Adding 
to this, the recent legal changes in the UK, and changes in legislation which will and 
have already taken place in other countries, will naturally make studying these 
substances even more problematic, and ultimately the work of front line workers 
more difficult. What is clear is that we can learn from previous examples of changes 
in controls over substances, and that in general once a psychoactive substance 
appears and gains some popularity, its use is unlikely to disappear. To help 
practitioners understand the use of NPS we can at least look to the fact that most of 
these substances have been designed to mimic, at least in part, the effects of 
‘classic’ recreational drugs, and so there is much we can understand by mapping 
across from this wider knowledge base, alongside new information as if becomes 
available: from bodies such as the EMCDDA and NEPTUNE15, as well as from the 
academic literature base. What we know so far about many NPS, and importantly, 
the categories of drug to which they belong, can help to inform current practices of 
UK practitioners and front line staff (see for example the suggested guidance in table 
2). In turn, the experiences of these staff will also be a key part in helping to map the 
changes in the NPS market and in expanding our understanding of the nature and 
extent of problems in users. 
 
About the authors 
 
Dr John Turner is a Reader in Psychopharmacology at the University of East 
London, and has researched recreational drugs for over 20 years. He currently leads 
the Drugs and Addictions Research Group at UEL and in addition to work looking at 
NPS, he is also currently engaged in e-cigarette research, vaping of illicit substances 
and problem gambling treatment. Previously his research has looked at 
8 
 
MDMA/ecstasy use in clubbers and young pregnant women (the effects on their 
infant’s development) and use of multiple recreational substances. 
 
Dr Kirstie Soar is a Principal Lecturer at the University of East London, specialising 
in drug research. Her work has examined the short and long term consequences of 
MDMA/ecstasy use, polydrug use and most recently the effects of recreational (non-
addicted) cocaine use on cognitive functioning. Other recent projects have explored 
the use of alcohol gels, cannabis vaping and e-cigarettes. 
 
 
 
 
 
References 
1. Winstock A R, & Ramsey J D. Legal highs and the challenges for policy 
makers. Addiction 2010; 105(10):1685-1687. 
2. European Monitoring Centre for Drugs and Drug Addiction.)New 
psychoactive substances in Europe. An update from the EU Early Warning 
System (March 2015), Publications Office of the European Union, 
Luxembourg. (Online.) www.emcdda.europa.eu/publications/2015/new-
psychoactive-substances (accessed 30 November 2016). 
3. Psychoactive Substances Act 2016, Chapter 2. London: The Stationary 
Office. (Online.) 
www.legislation.gov.uk/ukpga/2016/2/pdfs/ukpgaen_20160002_en.pdf 
(accessed 30 November 2016). 
4. Wood D.M, Measha, F, & Dargan P I.  ‘Our favourite drug’: prevalence of 
use and preference for mephedrone in the London night-time economy 1 
year after control. Journal of Substance Use 2012; 17(2):91-97. 
5. Corazza O, Simonato P, Corkery J, Trincas G., Schifano F.  "Legal highs": safe 
and legal "heavens"? A study on the diffusion, knowledge and risk 
awareness of novel psychoactive drugs among students in the UK. Rivista 
Di Psichiatria 2014, 49(2), 89-94. 
6. Schmidt MM, Sharma A, Schifano F, Feinmann C. ‘Legal highs’ on the net – 
evaluation of UK-based websites, products and product information. 
Forensic Sci Int.2011;Mar20; 206(1–3): 92–7.  
9 
 
7. Karila L, Megarbane B, Cottenci, O, & Lejoyeu, M. Synthetic cathinones: a 
new public health problem. Current neuropharmacology 2015; 13(1): 12-
20. 
8. Vandrey R, Dunn KE, Fry JA, Girling ER. A survey study to characterize use of 
Spice products (synthetic cannabinoids). Drug Alcohol Depend2012; Jan 1; 
120(1-3):238–41.  
9. Rosenbaum CD, Carreiro SP, Babu KM.  Here today, gone tomorrow….and 
back again? A review of herbal marijuana alternatives (K2, Spice), synthetic 
cathinones (bath salts, kratom, Salvia divinorum, methoxetamine, and 
piperazines. Journal of medical toxicology 2012; 8:15-32. 
10. Papanti D, Schifano F. Botteon G, Bertossi F, Mannix J, Vidon, D. 
"Spiceophrenia": a systematic overview of "Spice"-related 
psychopathological issues and a case report. Human Psychopharmacology 
2013; 28(4): 379-389. 
11. Winstock AR, Barratt M.  The 12 month prevalence and nature of adverse 
experiences resulting in emergency medical presentations associated with 
the use of synthetic cannabis products. Human Psychopharmacology 2013;, 
28(9):390-393. 
12. Hurst D, Loeffler G, McLay R. Synthetic cannabinoid agonist induced 
psychosis a case series. APA poster. Naval Medical Centre, San Diego, 2011. 
http://www.ncis.navy.mil/PI/CRP/Documents/ 
Spice%20APA%20poster.pdf.  
13. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz 
K. Withdrawal phenomena and dependence syndrome after the 
consumption of “spice gold.” 2009. doi:  10.3238/arztebl.2009.0464 
14. Winstock AR, Mitcheson LR, Deluca P, et al. Mephedrone, new kid for the 
chop? Addiction; 2011; 106(1):154–61. 
15. Abdulrahim D & Bowden-Jones O, on behalf of the NEPTUNE Expert Group. 
Guidance on the Management of Acute and Chronic Harms of Club Drugs 
and Novel Psychoactive Substances. Novel Psychoactive Treatment UK 
Network (NEPTUNE). London, 2015. 
16. Hill SL, Thomas SH. Clinical toxicology of newer recreational drugs. doi: 
10.3109/15563650.2011.615318. 
 
 
 
 
PQs: 
10 
 
Staying abreast of the myriad of substances available and their possible impact is a 
challenge for us all, and has become more so in recent years with the rise of novel 
psychoactive substances 
 
awareness informs compassion and understanding and helps in coping with anxiety 
when working with issues beyond our own direct experience 
 
the effects of long term exposure and follow-up profiles of affected users are under-
researched, although one study has shown evidence of prolonged psychosis in a 
small subset of users 
 
many of these substances, possibly at lower doses, could seen by some users as 
aiding study/work, reducing fatigue and need for sleep, and as enhancing 
concentration and performance 
 
Studies to date do … raise significant concerns about the harm related to use of 
many of these substances 
